New interventions on pump.science aim to push lifespan extension beyond single pathways and into bold combination therapies.
Rapamycin has long been the poster child of geroscience, reliably extending lifespan in multiple species and producing an enviable array of healthspan benefits; yet no single molecule can shoulder the weight of the longevity field indefinitely. Rapamycin Longevity Lab (RLL), which has already turned heads with the performance of Omipalisib on the pump.science platform, is now broadening its reach, adding renowned scientists to its leadership team and launching three new interventions designed to push beyond the familiar boundaries of mTOR inhibition.
With Brian Kennedy, one of the pioneers of the geroscience field and former CEO of the Buck Institute, joining as scientific advisor, and Kamil Pabis, translational aging researcher and bioinformatics specialist, taking on the role of scientific lead, RLL is positioning itself as one of the most ambitious and scientifically rigorous projects in the decentralized longevity research space.
Longevity.Technology: Rapamycin has long been the headline act in geroscience – dependable, durable, but perhaps too dominant. Its ability to extend lifespan across organisms is not in doubt, but a field cannot live on a single pathway alone; diversification is both a scientific necessity and a survival strategy. The Rapamycin Longevity Lab’s decision to reach beyond its namesake compound is less a departure than an evolution, acknowledging that longevity will not be won by one molecule, but by combinations, synergies and the courage to test hypotheses that do not fit neatly into the conventional drug-development mold.
What is striking here is not only the science but the structure – a decentralized platform that lets experiments unfold in the open, funded by the very community that hopes to benefit from them. Pump.science may strike some as gimmickry, yet it has demonstrated an unnerving ability to mobilize capital and attention at speed; it transforms the old bottlenecks of grant cycles and guarded data into something more fluid, more immediate, more public. Whether this model matures into a credible engine for translational geroscience remains to be seen, but it does force the question of how best to finance a field that seeks to delay decline rather than treat disease.
From Rapamycin to Omipalisib and beyond
“Rapamycin Longevity Lab recognizes the longevity impact of targeting mTOR but also the limitations of stopping with rapamycin or targeting mTOR alone. That’s why we’re focused on developing mTOR-inhibitor-based combination therapies. We’re not just trying to add a few more years, we’re exploring how far we can truly push the boundaries of human longevity,” says Krister Kauppi, Co-founder, Rapamycin Longevity Lab.
RLL’s founding mission has been to extend rapamycin’s legacy by leveraging ultra-high-throughput lifespan assays – capable of operating up to 1000 times faster than conventional models – together with AI-driven compound selection and mechanistic interrogation to uncover synergistic interventions beyond single-agent mTOR inhibition. Its first breakthrough came with Omipalisib, a dual PI3K/mTOR inhibitor that extended C elegans lifespan by 63%, nearly doubling the gains seen with rapamycin alone [1].
This success was amplified by pump.science, the decentralized platform that enables anyone to fund, follow and trade interventions as crypto tokens, with trading fees diverted directly into in vivo experiments. Omipalisib’s token, $OMIPAL, drew rapid community uptake, funding worm and fly studies within hours and mouse studies within weeks, and ultimately earning the title of “King of the Pill.”
pump.science: A new crypto-powered research engine
“The field has fixated on a narrow set of interventions that have shown preliminary success in preclinical models. But to achieve meaningful lifespan extension, we need to explore a much broader chemical space. Platforms like pump.science allow us to rapidly fund the experiments that collect this data in a way that balances speed, rigor, and transparency,” says Brian Kennedy, Scientific Advisor, Rapamycin Longevity Lab.
By transforming longevity research into a rapid, transparent and community-funded process, pump.science reframes how experiments are initiated and validated. Each compound is represented by a token, its trading activity feeding directly into lifespan trials in worms, flies and eventually mammals. Results are openly visible on the platform, creating a living dataset that anyone can interrogate.
“Longevity biotech is trying to make it in a system built to treat disease. The machine forces companies to pick a single disease, raise equity, lock up IP, and clear the FDA gauntlet. Every longevity biotech is dying on that hill. That isn’t science failing—it’s incentives pointing in the wrong direction. pump.science is rebuilding the longevity biotech engine: aligning objectives, capital, and protocols around one outcome—more life. Here, anyone can fund research, analyze the data, and push interventions forward in the open. That’s how we break the longevity doom cycle and push human lifespan higher,” says Benji Leibowitz, Founder, pump.science.
New interventions launched
RLL has now rolled out three new interventions on pump.science, all launched within a week and quickly funded for worm, fly and mouse studies. The rapid uptake reflects both the appetite within the pump.science community and the momentum generated by Omipalisib’s earlier success. Each compound comes with a different degree of novelty, risk and translational potential, but all share the same underlying rationale – to test whether combining known mechanisms can push lifespan extension further than single agents ever could.
Doxycycline ($DOCS)
A widely used antibiotic with decades of safety data, doxycycline has shown lifespan extension of up to 95% in C elegans and 34% in flies, with mechanisms linked to mitochondrial stress responses, improved proteostasis and anti-inflammatory signaling [2]. It has also shown promise in models of neurodegeneration, adding to its appeal as a potential repurposed longevity therapeutic.
“Doxycycline is an exciting drug because it’s safe, already used for a variety of human conditions, and has compelling evidence to be repurposed for longevity at lower dosages through its anti-inflammatory and mitochondrial actions, not just antimicrobial effects,” says Kamil Pabis, Research Scientist, Rapamycin Longevity Lab.
Omipalisib + Doxycycline ($OMIDOCS)
A bold combination targeting PI3K/mTOR alongside mitochondrial resilience, this pairing achieved a median lifespan extension of up to 109% in C elegans [2].
“This combo is novel, promising, and can have a major impact on human longevity if its potential shines through and replicates across preclinical models, but optimizing dosing will be critical to maximize effects. It’s the kind of hypothesis we can test quickly and transparently through pump.science,” says Kauppi.
Rapamycin + Doxycycline
A more conservative synergy, both drugs are FDA-approved and supported by safety data. This combination offers a real-world translational opportunity if results in model organisms are replicated.
“This combination of mTOR inhibitor, anti-inflammatory, and mitochondrial hormesis deserves serious exploration in real world studies. The beauty of this compound is that it offers promise to make real world, real-time impact as both interventions are FDA-approved with robust safety records at low dosages,” says Pabis.
The path ahead
With Kennedy and Pabis now embedded, RLL unites scientific rigor with decentralized funding mechanisms, aiming to accelerate discovery and validation. The pump.science platform allows compounds to be tested not in isolation but side-by-side, using standardized in vivo protocols and transparent reporting.
“We need more bold, decentralized exploration of potential longevity-enhancing candidates, especially if we want to leap beyond the same old interventions we’ve been stuck on for decades, garner more interest in the field, and expand the horizons of what’s possible. That’s what Rapamycin Longevity Lab and pump.science are enabling,” says Kennedy.
Whether through Omipalisib, Rapamycin-Doxycycline or other novel combinations yet to come, the message is clear: the next phase of geroscience will not be driven by single agents but by combinations, communities and the willingness to rethink how longevity research is resourced and delivered.
[1] https://masteronething.com/lid?filter=GSK2126458
[2] https://onlinelibrary.wiley.com/doi/10.1111/acel.14424
